| Literature DB >> 32011687 |
Revital Bronstein1, Elizabeth E Capowski2, Sudeep Mehrotra1, Alex D Jansen2, Daniel Navarro-Gomez1, Mathew Maher1, Emily Place1, Riccardo Sangermano1, Kinga M Bujakowska1, David M Gamm3, Eric A Pierce1.
Abstract
Inherited retinal degenerations (IRDs) are at the focus of current genetic therapeutic advancements. For a genetic treatment such as gene therapy to be successful, an accurate genetic diagnostic is required. Genetic diagnostics relies on the assessment of the probability that a given DNA variant is pathogenic. Non-coding variants present a unique challenge for such assessments as compared to coding variants. For one, non-coding variants are present at much higher number in the genome than coding variants. In addition, our understanding of the rules that govern the non-coding regions of the genome is less complete than our understanding of the coding regions. Methods that allow for both the identification of candidate non-coding pathogenic variants and their functional validation may help overcome these caveats allowing for a greater number of patients to benefit from advancements in genetic therapeutics. We present here an unbiased approach combining whole genome sequencing (WGS) with patient-induced pluripotent stem cell (iPSC)-derived retinal organoids (ROs) transcriptome analysis. With this approach, we identified and functionally validated a novel pathogenic non-coding variant in a small family with a previously unresolved genetic diagnosis.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32011687 PMCID: PMC7158377 DOI: 10.1093/hmg/ddaa016
Source DB: PubMed Journal: Hum Mol Genet ISSN: 0964-6906 Impact factor: 6.150